Close
Help




JOURNAL

Clinical Medicine Reviews in Vascular Health

Alogliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Submit a Paper


Clinical Medicine Reviews in Vascular Health 2011:3

Review

Published on 22 Feb 2011

DOI: 10.4137/CMRVH.S3318


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Vascular Health

Abstract

Alogliptin benzoate is a DPP-4 inhibitor currently in Phase 3 clinical trials in the United States for treatment of T2DM. Alogliptin is approved and available for use in Japan for the treatment of T2DM. Alogliptin has been studied clinically as initial therapy in treatment naïve patients with T2DM, as initial therapy in combination with pioglitazone, and as add-on therapy to T2DM patients with inadequate control on metformin, glyburide, pioglitazone, and insulin. Clinical trial data with alogliptin demonstrate clinical efficacy in terms of A1C and FPG reductions when used both as monotherapy and in combination with other oral antidiabetic medications. Overall, alogliptin is generally well tolerated when used as monotherapy and in combination with concomitant oral antidiabetic therapy. Comparative studies are needed to determine the clinical advantages, if any, of alogliptin when compared with other currently available DPP-4 inhibitors.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Reviews in Vascular Health
Publishing in Clinical Medicine Reviews in Vascular Health was a pleasant experience. The process was fast and fair. The staff were very professional and we were well informed of the progress of the manuscript.
Dr Abd A Tahrani MD (Birmingham Heartlands Hospital, University of Birmingham, UK)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube